KalVista Pharmaceuticals Management

Management criteria checks 3/4

KalVista Pharmaceuticals' CEO is Ben Palleiko, appointed in Mar 2024, has a tenure of less than a year. total yearly compensation is $2.42M, comprised of 21.3% salary and 78.7% bonuses, including company stock and options. directly owns 0.44% of the company’s shares, worth €1.88M. The average tenure of the management team and the board of directors is 3.9 years and 4.1 years respectively.

Key information

Ben Palleiko

Chief executive officer

US$2.4m

Total compensation

CEO salary percentage	21.3%
CEO tenure	less than a year
CEO ownership	0.4%
Management average tenure	3.9yrs
Board average tenure	4.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ben Palleiko's remuneration changed compared to KalVista Pharmaceuticals's earnings?
Date	Total Compensation	Salary	Company Earnings
Jan 31 2024	n/a	n/a	-US$108m
Oct 31 2023	n/a	n/a	-US$101m
Jul 31 2023	n/a	n/a	-US$95m
Apr 30 2023	US$2m	US$515k	-US$93m
Jan 31 2023	n/a	n/a	-US$91m
Oct 31 2022	n/a	n/a	-US$92m
Jul 31 2022	n/a	n/a	-US$89m
Apr 30 2022	US$3m	US$490k	-US$82m
Jan 31 2022	n/a	n/a	-US$73m
Oct 31 2021	n/a	n/a	-US$61m
Jul 31 2021	n/a	n/a	-US$52m
Apr 30 2021	US$1m	US$435k	-US$46m
Jan 31 2021	n/a	n/a	-US$38m
Oct 31 2020	n/a	n/a	-US$37m
Jul 31 2020	n/a	n/a	-US$33m
Apr 30 2020	US$1m	US$435k	-US$29m
Jan 31 2020	n/a	n/a	-US$31m
Oct 31 2019	n/a	n/a	-US$26m
Jul 31 2019	n/a	n/a	-US$23m
Apr 30 2019	US$2m	US$366k	-US$21m
Jan 31 2019	n/a	n/a	-US$13m
Oct 31 2018	n/a	n/a	-US$14m
Jul 31 2018	n/a	n/a	-US$16m
Apr 30 2018	US$821k	US$340k	-US$16m
Jan 31 2018	n/a	n/a	-US$19m
Oct 31 2017	n/a	n/a	-US$22m
Jul 31 2017	n/a	n/a	-US$21m
Apr 30 2017	US$924k	US$239k	-US$21m

Compensation vs Market: Ben's total compensation ($USD2.42M) is above average for companies of similar size in the German market ($USD1.02M).

Compensation vs Earnings: Ben's compensation has been consistent with company performance over the past year.

CEO

Ben Palleiko (57 yo)

less than a year

Tenure

US$2,420,747

Compensation

Mr. Benjamin L. Palleiko, also known as Ben, has been Director and Chief Executive Officer of KalVista Pharmaceuticals, Inc. from March 07, 2024. He served as President of KalVista Pharmaceuticals, Inc. fr...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Benjamin Palleiko	CEO & Director	less than a year	US$2.42m	0.44% $ 1.9m
Christopher Yea	Chief Development Officer	8.4yrs	US$1.65m	0.17% $ 732.9k
Edward Feener	Chief Scientific Officer	7.4yrs	US$1.59m	0.15% $ 624.9k
Ryan Baker	Head of Investor Relations	no data	no data	no data
Brian Krex	General Counsel	no data	no data	no data
Jarrod Aldom	Vice President of Corporate Communications	no data	no data	no data
Rachel Morten	Senior Vice President of Regulatory Affairs & QA	no data	no data	no data
Michael Smith	Senior Vice President of Development	4.9yrs	no data	no data
Paul Audhya	Chief Medical Officer	2.9yrs	no data	0.13% $ 531.8k
Nicole Sweeny	Chief Commercial Officer	less than a year	no data	no data
Stephen Donnelly	Director of Finance and Company Secretary	no data	no data	no data

3.9yrs

Average Tenure

55yo

Average Age

Experienced Management: 4XC1's management team is considered experienced (3.9 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Benjamin Palleiko	CEO & Director	less than a year	US$2.42m	0.44% $ 1.9m
Edward Unkart	Independent Director	9.3yrs	US$94.06k	0% $ 0
Albert Cha	Independent Director	16.4yrs	US$89.06k	0% $ 0
Brian J. Pereira	Independent Chairman	5.2yrs	US$107.85k	0% $ 0
Nancy Stuart	Independent Director	3.1yrs	US$89.58k	0% $ 0
William Fairey	Director	no data	no data	no data
Tomas Kiselak	Board Observer	8.8yrs	no data	no data
Patrick Treanor	Independent Director	1.9yrs	US$159.18k	0% $ 0

4.1yrs

Average Tenure

57.5yo

Average Age

Experienced Board: 4XC1's board of directors are considered experienced (4.1 years average tenure).

KalVista Pharmaceuticals Management

Management criteria checks 3/4

Key information

Recent management updates

Kalvista Pharmaceuticals, Inc. Appoints William C. Fairey to the Board of Directors

KalVista Pharmaceuticals, Inc. Announces Board Changes

CEO & Director recently sold €817k worth of stock

KalVista Pharmaceuticals, Inc., Annual General Meeting, Sep 26, 2023

KalVista Pharmaceuticals, Inc. Appoints Nicole Sweeny as Chief Commercial Officer

Kalvista Pharmaceuticals Announces Benjamin L. Palleiko Promoted to President

Recent updates

Kalvista Pharmaceuticals, Inc. Appoints William C. Fairey to the Board of Directors

KalVista Pharmaceuticals, Inc. to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas

KalVista Pharmaceuticals, Inc. Announces Board Changes

KalVista Pharmaceuticals, Inc. Receives UK Innovation Passport for Sebetralstat from UK Medicines and Healthcare Products Regulatory Agency

KalVista Pharmaceuticals, Inc. Receives UK Innovation Passport for Sebetralstat from UK Medicines and Healthcare Products Regulatory Agency

CEO & Director recently sold €817k worth of stock

KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

KalVista Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

New major risk - Share price stability

Kalvista Pharmaceuticals, Inc. Reports Phase 3 Konfident Trial Meets All Endpoints for Sebetralstat as First Oral On-Demand Therapy for Hereditary Angioedema

New minor risk - Profitability

New major risk - Financial position

Kalvista Pharmaceuticals Announces Phase 3 Konfident Trial Milestone Achieved

KalVista Pharmaceuticals to Present Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology

KalVista Pharmaceuticals, Inc., Annual General Meeting, Sep 26, 2023

KalVista Pharmaceuticals, Inc. Appoints Nicole Sweeny as Chief Commercial Officer

KalVista Pharmaceuticals, Inc. Presents New Data at 2023 Meeting of the European Academy of Allergy and Clinical Immunology

KalVista Pharmaceuticals, Inc. Presents Data At 13Th C1-Inhibitor Deficiency & Angioedema Workshop

KalVista Pharmaceuticals, Inc. Provides Progress Updates on Sebetralstat Development

Kalvista Pharmaceuticals Announces Publication of Sebetralstat Phase 2 Data in the Lancet

Kalvista Pharmaceuticals Announces Benjamin L. Palleiko Promoted to President

KalVista Pharmaceuticals Presents Patient-Focused Data at American College of Allergy, Asthma & Immunology (ACAAI) 2022 Meeting

Kalvista Pharmaceuticals Announces Positive Phase 1 Data for Orally Disintegrating Tablet Formulation of Sebetralstat for Use in Hereditary Angioedema

KalVista Pharmaceuticals, Inc. Announces Management Changes

KalVista Pharmaceuticals, Inc. Presents New Patient-Centric Data at 2022 HAEi Global Leadership Workshop

KalVista Pharmaceuticals Announces Termination of KVD824 Phase 2 KOMPLETE Trial for Prophylactic Treatment of Hereditary Angioedema

Kalvista Pharmaceuticals, Inc. Announces Initiation of KONFIDENT-S Open Label Extension Study for Sebetralstat in Hereditary Angioedema

KalVista Pharmaceuticals, Inc., Annual General Meeting, Oct 13, 2022

No longer forecast to breakeven

KalVista Pharmaceuticals, Inc. Announces Board Changes

KalVista Pharmaceuticals, Inc. Presents Data Showing Rapid Reduction of Plasma Kallikrein Activity After Oral KVD900 Treatment and Early Symptom Relief from HAE Attacks in Patients

KalVista Pharmaceuticals, Inc. to Present Data on Oral On-Demand HAE Therapy KVD900 at AAAAI 2022

U.S. Food and Drug Administration Lifts the Clinical Hold on Kalvista Pharmaceuticals, Inc.’s Phase 2 Clinical Trial of KVD824 for Oral Prophylactic Treatment of Hereditary Angioedema

KalVista Pharmaceuticals, Inc. Provides Progress Update on Phase 2 Clinical Trial of KVD824 for Oral Prophylactic Treatment of Hereditary Angioedema

KalVista Pharmaceuticals Presents Data Showing Single On-Demand Treatment with Orally Administered KVD900 Significantly Slows Progression and Accelerates Resolution of Attacks in Patients with HAE

KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) dropped from Russell 3000E Value Index

KalVista Pharmaceuticals Presents Phase 2 Clinical Data of Oral KVD900 for Treatment of HAE at C1-Inhibitor Deficiency & Angioedema Workshop

KalVista Pharmaceuticals, Inc. Appoints Nancy Stuart to Board of Directors and Audit Committee

Revenue misses expectations

KalVista Pharmaceuticals Reports Positive Results for KVD900 Phase 2 Demonstrating Statistically and Clinically Significant Responses Across All Endpoints as an Oral On-Demand Treatment for HAE Attacks

New 90-day low: €12.50

Kalvista Pharmaceuticals, Inc. Provides Data on Kvd824 as Twice-Daily Oral Candidate for Prophylactic Treatment of Hae; Announces Novel Oral Factor Xiia Inhibitor Program as the Next Area of Development Focus

Revenue misses expectations

Kalvista Pharmaceuticals, Inc. Reports Demise of Arnold Oronsky on November 21, 2020

New 90-day high: €16.20

KalVista Pharmaceuticals, Inc. Announces Updated Guidance on the Data Release of Its Phase 2 Clinical Trial

New 90-day high: €14.60

KalVista Pharmaceuticals Provides Update on Oral Hereditary Angioedema Franchise

New 90-day high: €11.90

New 90-day high - €11.60

First quarter earnings released

New 90-day high - €11.50

New 90-day low - €8.55

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age